Chinese Journal of Polymer Science, Journal Year: 2022, Volume and Issue: 41(3), P. 327 - 333
Published: Sept. 21, 2022
Language: Английский
Journal of Biomedical Science, Journal Year: 2023, Volume and Issue: 30(1)
Published: Oct. 16, 2023
Abstract RNA has emerged as a revolutionary and important tool in the battle against emerging infectious diseases, with roles extending beyond its applications vaccines, which it is used response to COVID-19 pandemic. Since their development 1990s, interference (RNAi) therapeutics have demonstrated potential reducing expression of disease-associated genes. Nucleic acid‐based therapeutics, including RNAi therapies, that degrade viral genomes rapidly adapt mutations, alternative treatments. robust technique frequently employed selectively suppress gene sequence-specific manner. The swift adaptability nucleic such therapies endows them significant advantage over other antiviral medications. For example, small interfering RNAs (siRNAs) are produced on basis sequence complementarity target RNA, novel approach combat infections. precision siRNAs targeting degrading led siRNA-based treatments for diverse diseases. However, despite promising therapeutic benefits siRNAs, several problems, impaired long-term protein expression, siRNA instability, off-target effects, immunological responses, drug resistance, been considerable obstacles use therapies. This review provides an encompassing summary approaches viruses while also addressing need be overcome effective application. Furthermore, we present solutions mitigate major challenges.
Language: Английский
Citations
59
Asian Journal of Pharmaceutical Sciences, Journal Year: 2022, Volume and Issue: 17(6), P. 817 - 837
Published: Nov. 1, 2022
The liposome is the first nanomedicine transformed into market and applied to human patients. Since then, such phospholipid bilayer vesicles have undergone technological advancements in delivering small molecular-weight compounds biological drugs. Numerous investigations about uses were conducted different treatment fields, including anti-tumor, anti-fungal, anti-bacterial, clinical analgesia, owing liposome's ability reduce drug cytotoxicity improve therapeutic efficacy combinatorial delivery. In particular, two liposomal vaccines approved 2021 combat COVID-19. Herein, clinically used liposomes are reviewed by introducing various preparations detail that currently proceeding clinic or on market. Finally, we discuss challenges of developing cutting-edge delivery for drugs combination therapy.
Language: Английский
Citations
37
Antiviral Research, Journal Year: 2023, Volume and Issue: 217, P. 105677 - 105677
Published: July 20, 2023
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a respiratory virus that causes COVID-19 disease, with an estimated global mortality of approximately 2%. While response strategies, which are predominantly reliant on regular vaccinations, have shifted from zero COVID to living COVID, there distinct lack broad-spectrum direct acting antiviral therapies maintain efficacy across evolving SARS-CoV-2 variants concern. This most concern for immunocompromised and immunosuppressed individuals who robust immune responses following vaccination, others at risk severe long-COVID. RNA interference (RNAi) therapeutics induced by short interfering RNAs (siRNAs) offer promising treatment option, capabilities unparalleled current high genetic barrier escape. Here we describe novel siRNAs, targeting highly conserved regions the SARS-CoV-1 genome both human animal species, multi-variant potency against eight lineages - Ancestral VIC01, Alpha, Beta, Gamma, Delta, Zeta, Kappa Omicron. Treatment our siRNA resulted in significant protection virus-mediated cell death vitro, >97% survival (P < 0.0001), corresponding reductions viral nucleocapsid up 99.9% 0.0001). When compared antivirals; Sotrovimab Remdesivir, siRNAs demonstrated more potent effect similarly, when multiplexing target different simultaneously, increased was observed individual treatments These results demonstrate potential effective multiple variants, including resistant antivirals vaccine generated neutralizing antibodies.
Language: Английский
Citations
15
International Journal of Biological Macromolecules, Journal Year: 2024, Volume and Issue: 275, P. 133680 - 133680
Published: July 4, 2024
Proteolysis targeting chimeras (PROTACs) can use the intrinsic protein degradation system in cells to degrade pathogenic target proteins, and are currently a revolutionary frontier of development strategy for tumor treatment with small molecules. However, poor water solubility, low cellular permeability, off-target side effects most PROTACs have prevented them from passing preclinical research stage drug development. This requires appropriate delivery systems overcome these challenging hurdles ensure precise towards site. Therefore, combination multifunctional will open up new directions targeted proteins. In this review, we systematically reviewed design principles recent advances various systems. Moreover, constructive strategies developing were proposed comprehensively. review aims deepen understanding drugs promote further system.
Language: Английский
Citations
6
Antiviral Research, Journal Year: 2024, Volume and Issue: 226, P. 105879 - 105879
Published: April 9, 2024
Treatment options for COVID-19 remain limited. Here, we report the optimization of an siRNA targeting highly conserved leader region SARS-CoV-2. The was rendered nuclease resistant by introduction modified nucleotides without loss activity. Importantly, also retained its inhibitory activity against emerged omicron sublineage variant BA.2, which occurred after designed and is to other antiviral agents such as antibodies. In addition, show that a second active viral 5'-UTR can be applied rescue molecule, minimize spread escape mutations. We therefore consider our siRNA-based molecules promising broadly candidates treatment current future SARS-CoV-2 variants.
Language: Английский
Citations
5
Computational and Structural Biotechnology Journal, Journal Year: 2025, Volume and Issue: unknown
Published: March 1, 2025
Language: Английский
Citations
0
DNA and Cell Biology, Journal Year: 2025, Volume and Issue: unknown
Published: May 5, 2025
Sepsis is a serious systemic inflammatory condition triggered by variety of pathogens, including bacteria and viruses, that can result in multiple organ failure life-threatening situation. Despite advances medical care, the mortality rate for sepsis remains high even with aggressive treatment strategies such as antibiotic therapy, fluid resuscitation, respiratory circulatory support. Extracellular vesicles (EVs), novel nanoscale biocarrier, exhibit diverse biological functions immune modulation tissue regeneration, suggesting promising applications field. This article provides an overview therapeutic effects EVs derived from various sources management sepsis. Furthermore, not only possess intrinsic properties, modulation, but also function targeted delivery vehicles drug molecules, leading to synergistic outcomes. In conclusion, extracellular vesicle therapy poised emerge dynamic innovative force driving advancements treatment.
Language: Английский
Citations
0
Frontiers in Bioengineering and Biotechnology, Journal Year: 2023, Volume and Issue: 11
Published: Feb. 6, 2023
Small interfering RNA (siRNA)-mediated mRNA degradation approach have imparted its eminence against several difficult-to-treat genetic disorders and other allied diseases. Viral outbreaks resulting pandemics repeatedly threatened public health questioned human preparedness at the forefront of drug design biomedical readiness. During recent pandemic caused by SARS-CoV-2, mRNA-based vaccination strategies paved way for a new era therapeutics. Interference (RNAi) based using small may complement clinical management COVID-19. will primarily work restricting synthesis proteins required viral replication, thereby hampering cellular entry trafficking targeting host as well protein factors. Despite promising benefits, stability in physiological environment is grave concern site-directed targeted delivery evasion immune system require immediate attention. In this regard, nanotechnology offers viable solutions these challenges. The review highlights potential RNAs toward specific regions genome features nanoformulations necessary entrapment RNAs. silico different variants SARS-CoV-2 has been discussed. Various nanoparticles carriers along with their salient properties, including surface functionalization, are summarized. This help tackle real-world challenges encountered vivo RNAs, ensuring safe, stable, readily available candidate efficient future.
Language: Английский
Citations
8
RNA Biology, Journal Year: 2024, Volume and Issue: 21(1), P. 1 - 18
Published: Dec. 4, 2024
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes the disease 2019 (COVID-19) pandemic and is continuously spreading globally. continuous emergence of new SARS-CoV-2 variants keeps posing threats, highlighting need for fast-acting, mutation-resistant broad-spectrum therapeutics. Protein translation vital replication, producing early non-structural proteins RNA replication transcription, late structural virion assembly. Targeted blocking viral protein thus a potential approach to developing effective anti-SARS-CoV-2 drugs. SARS-CoV-2, as an obligate parasite, utilizes host's machinery. Translation-blocking strategies that target mRNA, especially those its conserved elements are generally preferred. In this review, we discuss current understanding translation, important motifs structures involved in regulation. We also through degradation or element dysfunction.
Language: Английский
Citations
2
Viruses, Journal Year: 2022, Volume and Issue: 15(1), P. 100 - 100
Published: Dec. 29, 2022
COVID-19, caused by SARS-CoV-2, created a devastating outbreak worldwide and consequently became global health concern. However, no verifiable, specifically targeted treatment has been devised for COVID-19. Several emerging vaccines have used, but protection not satisfactory. The complex genetic composition high mutation frequency of SARS-CoV-2 an uncertain vaccine response. Small interfering RNA (siRNA)-based therapy is efficient strategy to control various infectious diseases employing post-transcriptional gene silencing through the target complementary mRNA. Here, we designed two highly effective shRNAs targeting conserved region RNA-dependent polymerase (RdRP) spike proteins capable significant replication suppression. efficacy this approach suggested that rapid development shRNA-based therapeutic might prove be in treating it needs further clinical trials.
Language: Английский
Citations
7